$20.08
-1.2%Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Chief Business & Strategy Officer
Compensation
$619,841
Chief Development Officer
Chief Financial Officer
Chief Legal Officer & Corporate Secretary
Chief Medical Officer
Chief Scientific Officer
Compensation
$651,368
President, Chief Executive Officer & Chairman
Compensation
$912,638
Senior Vice President & Head of Immunology and Translational Science
Senior Vice President of People & Culture
Senior Vice President of Pharmacology & Project Team Leader
During the last 12 months, insiders have purchased $22.40M worth of ALMS shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
705.9K
12.00M
0
0.00
+12.0M
+$12.00M
1.3M
9.22M
0
0.00
+9.2M
+$9.22M
289.0K
1.18M
0
0.00
+1.2M
+$1.18M
Akkaraju Srinivas
Director
$15.01M
Foresite Labs, Llc
10 Percent Owner
$5.35M
Foresite Capital Management Vi Llc
10 Percent Owner
$533K
Tananbaum James B.
Director, 10 Percent Owner:
$533K
Tetrault Lynn A.
Director
$204K
No selling activity
Strong bullish signal with $22.40M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
ALMS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | May 18, 2026 | June 30, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | June 16, 2025 | July 30, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.